MedTrace Logo

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

NCT00547066 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-08-16

No results posted yet for this study

Summary

This trial will study different dose levels of hA20 (IMMU-106) to see if they are safe and effective for treating ITP.

Conditions

  • Purpura, Thrombocytopenic, Idiopathic
  • Autoimmune Thrombocytopenic Purpura
  • Purpura, Thrombocytopenic, Autoimmune

Interventions

BIOLOGICAL

veltuzumab

hA20 will be administered intravenously in two doses over two weeks

Sponsors & Collaborators

Principal Investigators

  • William Wegener, MD, PHD · Gilead Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00547066 on ClinicalTrials.gov